

In the claims:

1-15. (Canceled).

16. (Previously presented) A Modified Vaccinia Ankara Virus vaccine vector which comprises a DNA construct which comprises DNA encoding one or more human cytomegalovirus proteins selected from the group consisting of pp65, pp150, IE1, gB and antigenic fragments thereof, wherein optionally one or more of said human cytomegalovirus proteins or antigenic fragments thereof is modified by N-terminal ubiquitination, N-end modification or both, and wherein said human cytomegalovirus protein or antigenic fragment thereof optionally contains a lysine-containing adapter sequence.

17. (Currently amended) A protein encoded by ~~the~~ a DNA construct of claim 16 which comprises DNA encoding one or more human cytomegalovirus proteins selected from the group consisting of pp65, pp150, IE1, gB and antigenic fragments thereof, wherein optionally one or more of said human cytomegalovirus proteins or antigenic fragments thereof is modified by N-terminal ubiquitination, N-end modification or both, and wherein said human cytomegalovirus protein or antigenic fragment thereof optionally contains a lysine-containing adapter sequence.

18. (Previously presented) A Modified Vaccinia Virus vaccine vector of claim 16 which comprises Ub-R-pp65, Ub-R-pp150, Ub-R-IE1(4) and gB(s).

19. (Currently amended) A DNA construct ~~of claim 16~~ which comprises DNA encoding one or more human cytomegalovirus proteins selected from the group consisting of pp65, pp150, IE1, gB and

antigenic fragments thereof, wherein optionally one or more of said human cytomegalovirus proteins or antigenic fragments thereof is modified by N-terminal ubiquitination, N-end modification or both, and wherein said human cytomegalovirus protein or antigenic fragment thereof optionally contains a lysine-containing adapter sequence, and wherein said DNA encodes:

- (a) ubiquitinated, N-terminal arginine, phosphokinase-deleted pp65;
- (b) ubiquitinated, N-terminal arginine pp150;
- (c) ubiquitinated, N-terminal arginine IE1 exon 4; and
- (d) transmembrane domain-deleted gB.

20. (Previously presented) A Modified Vaccinia Virus vaccine vector which comprises the DNA constructed in claim 19.

21. (Previously presented) A method of vaccinating a person in need thereof against human cytomegalovirus which comprises administering to said person an effective amount of the vaccine virus vector of claim 16.

22. (Previously presented) A method of augmenting immunity against human cytomegalovirus in a person in need thereof which comprises administering to said person an effective amount of the vaccine virus vector of claim 16.